Full-Time

Accounting Manager

Posted on 6/23/2025

Fractyl Health

Fractyl Health

51-200 employees

Therapies for Type 2 Diabetes

No salary listed

Mid, Senior

Burlington, MA, USA

In Person

Category
Financial Accounting
Management Accounting
Accounting
Requirements
  • Bachelor’s degree in Accounting or Finance; CPA or CPA-track preferred
  • 4–6 years total experience, ideally including public accounting and/or biotech/pharma industry exposure
  • Prior experience managing or supporting the accounts payable process, preferably in a growth-stage or biotech environment
  • Familiarity with biotech-specific topics such as R&D accruals, clinical trial accounting, or SOX readiness is a plus
  • Strong understanding of US GAAP
  • Experience with ERP systems (Microsoft Dynamics 365 preferred)
  • Eagerness to grow professionally and take on increasing responsibility
Responsibilities
  • Key player in the monthly, quarterly, and annual close processes, including preparation of journal entries, accruals (especially for R&D and clinical trials), and account reconciliations
  • Assist with overseeing the accounts payable function, ensuring timely and accurate processing of invoices, adherence to company policies, and appropriate coding of expenses
  • Prepare and maintain supporting schedules for key accounts, including prepaids, fixed assets, and accrued liabilities
  • Support timely preparation of financial statements in accordance with US GAAP
  • Play a key role in implementing new processes and systems
  • Aid in improvement of documentation of processes to support internal controls
  • Coordinate with external auditors during interim and year-end audits
  • Mentor junior staff and potentially oversee one or more accountants over time
  • Perform other related duties and ad-hoc projects as required
Desired Qualifications
  • Highly organized and detail-oriented with a passion to deliver quality results
  • Strong proficiency with Microsoft Excel
  • Ability to work with confidential information in a professional way
  • Effective team player – puts personal agenda aside and focuses on what’s best for the team
  • Desire and ability to work in a fast-paced environment. Ability to prioritize tasks effectively, managing multiple assignments simultaneously, and consistently delivering high-quality results within established timeframes

Fractyl Health focuses on creating therapies for Type 2 Diabetes (T2D) and obesity, targeting the root causes of these metabolic diseases. Their main product, Rejuva, is a gene therapy platform aimed at improving the function of pancreatic islet cells, which are essential for regulating blood sugar levels. By enhancing these cells, Fractyl seeks to achieve long-term remission for patients with T2D and obesity. Currently, Rejuva is in preclinical development and has received a CE mark for commercial availability in Europe, although it is still undergoing FDA oversight. Unlike many competitors, Fractyl's approach centers on gene therapy to address the underlying issues of these conditions rather than just managing symptoms. The company's goal is to develop transformative therapies that can prevent and eliminate T2D and obesity, ultimately improving patient health outcomes.

Company Size

51-200

Company Stage

IPO

Headquarters

Lexington, Kentucky

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Rejuva's CE mark approval aids European market expansion.
  • Partnership with Forge Biologics boosts gene therapy production capabilities.
  • Adrian Kimber's appointment strengthens commercialization strategies for Revita.

What critics are saying

  • Competition from established firms may impact Fractyl's market share.
  • FDA approval delays could hinder Rejuva's commercialization.
  • High gene therapy development costs may strain financial resources.

What makes Fractyl Health unique

  • Fractyl Health focuses on minimally invasive therapies for chronic diseases.
  • The Rejuva platform targets root causes of Type 2 Diabetes and obesity.
  • Fractyl's Revita DMR rejuvenates the duodenum lining to improve patient health.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
PharmaSource
May 15th, 2025
Forge Biologics Partners with Fractyl Health on AAV Manufacturing for Metabolic Gene Therapy

Forge Biologics partners with Fractyl Health on AAV manufacturing for metabolic gene therapy.

Newz9
May 13th, 2025
Fractyl Health Unveils Exciting First Quarter 2025 Financial Results and Key Business Updates

Fractyl is also working on a gene therapy platform called Rejuva.

GlobeNewswire
May 6th, 2025
Fractyl Health To Report First Quarter 2025 Financial Results And Provide Business Updates On May 13, 2025, And Will Participate In An Upcoming Investor Conference

BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET.A live webcast of the conference call can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 5:00 p.m. PT (8:00 p.m. ET).A live webcast of the presentation can be accessed in the “Events” section of Fractyl Health’s website at https://ir.fractyl.com/

Slater Sentinel
Mar 1st, 2025
Conservest Capital Advisors Inc. Makes New $132,000 Investment in Fractyl Health, Inc. (NASDAQ:GUTS)

Conservest Capital Advisors Inc. makes new $132,000 investment in Fractyl Health, Inc. (NASDAQ:GUTS).

Yahoo Finance
Apr 30th, 2024
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita(R) in patients with T2D in Germany

INACTIVE